HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sodium-Glucose Transporter 2

A sodium-glucose transporter that is expressed in the luminal membrane of the PROXIMAL KIDNEY TUBULES.
Also Known As:
SGLT2 Protein; SLC5A2 Protein; Sodium Glucose Transporter 2
Networked: 64 relevant articles (7 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Jhuo, Shih-Jie: 3 articles (02/2022 - 08/2020)
2. Lai, Wen-Ter: 3 articles (02/2022 - 08/2020)
3. Lee, Kun-Tai: 3 articles (02/2022 - 08/2020)
4. Lin, Yi-Hsiung: 3 articles (02/2022 - 08/2020)
5. Liu, I-Hsin: 3 articles (02/2022 - 08/2020)
6. Wu, Bin-Nan: 3 articles (02/2022 - 08/2020)
7. Qiu, Mei: 3 articles (03/2021 - 01/2021)
8. Tsai, Wei-Chung: 2 articles (02/2022 - 08/2020)
9. Zhao, Li-Min: 2 articles (11/2021 - 01/2021)
10. Katsiki, Niki: 2 articles (11/2021 - 12/2010)

Related Diseases

1. Type 2 Diabetes Mellitus (MODY)
2. Cardiovascular Diseases (Cardiovascular Disease)
3. Heart Failure
01/01/2022 - "Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies."
10/01/2019 - "Recent data has illustrated that sodium-glucose transporter 2 (SGLT2) inhibitor therapy can reduce the burden of heart failure and the progression of renal disease across a wide range of patients including those with and without established disease, supported by an increased understanding of the mechanistic effects of these agents. "
01/01/2022 - "Objective: The study aimed to evaluate the effect of sodium-glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF). "
01/01/2021 - "Patients with type 2 diabetes treated with Sodium glucose transporter 2 (SGLT2) inhibitors show reduced mortality and hospitalization for heart failure (HF). "
02/01/2023 - "Individual patient time-to-event information from Kaplan-Meier plots of cardiovascular mortality (CM) and/or hospitalization for heart failure (HHF) endpoints from cardiovascular outcome trials (CVOTs) evaluating dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium glucose transporter 2 (SGLT2) inhibitors vs. placebo were digitalized using WebPlotDigitizer 4.2 and the R code of Guyot et al.; Weibull regression models were generated, validated, and used to estimate NNT for individual trials; random-effects meta-analysis generated Meta-NNT with 95% confidence intervals. "
4. Diabetic Nephropathies (Diabetic Nephropathy)
5. Cognitive Dysfunction

Related Drugs and Biologics

1. Sodium-Glucose Transporter 2 Inhibitors
2. Glucose (Dextrose)
3. Hypoglycemic Agents (Hypoglycemics)
4. empagliflozin
5. Uric Acid (Urate)
6. Cardiovascular Agents
7. marein
8. Glucagon-Like Peptide 1 (GLP 1)
9. Proteins (Proteins, Gene)
10. remogliflozin etabonate

Related Therapies and Procedures

1. Therapeutics
2. Ketogenic Diet